196808-45-4
196808-45-4
Chemical Structure
Farglitazar
Synonym(s): GI262570; GI262570X
- CAS No.: 196808-45-4
- Formula:C34H30N2O5
- Molecular Weight:546.61
IUPAC Name: (S)-2-((2-benzoylphenyl)amino)-3-(4-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)phenyl)propanoic acid
InChIKey: ZZCHHVUQYRMYLW-HKBQPEDESA-N
SMILES: O=C(C1=CC=CC=C1)C2=C(C=CC=C2)N[C@H](C(O)=O)CC3=CC=C(C=C3)OCCC4=C(C)OC(C5=CC=CC=C5)=N4
Biological Activity: Farglitazar is a PPARγ agonist that has significant therapeutic benefits such as glycemic control in type 2 diabetic patients.
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Farglitazar | 99.50% | Farglitazar is a PPARγ agonist that has significant therapeutic benefits such as glycemic control in type 2 diabetic patients. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Farglitazar (Standard) | ≥98% | Farglitazar (Standard) is the analytical standard of Farglitazar (HY-105074). This product is intended for research and analytical applications. Farglitazar is a PPARγ agonist that has significant therapeutic benefits such as glycemic control in type 2 diabetic patients. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
